These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25482937)

  • 1. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.
    Sun Q; Zhou J; Zhang Z; Guo M; Liang J; Zhou F; Long J; Zhang W; Yin F; Cai H; Yang H; Zhang W; Gu Y; Ni L; Sai Y; Cui Y; Zhang M; Hong M; Sun J; Yang Z; Qing W; Su W; Ren Y
    Cancer Biol Ther; 2014; 15(12):1635-45. PubMed ID: 25482937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
    Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities.
    Alam A; Blanc I; Gueguen-Dorbes G; Duclos O; Bonnin J; Barron P; Laplace MC; Morin G; Gaujarengues F; Dol F; Hérault JP; Schaeffer P; Savi P; Bono F
    Mol Cancer Ther; 2012 Aug; 11(8):1637-49. PubMed ID: 22584122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics.
    Gu Y; Wang J; Li K; Zhang L; Ren H; Guo L; Sai Y; Zhang W; Su W
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):95-115. PubMed ID: 24817647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
    Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
    Gaumann AK; Drexler HC; Lang SA; Stoeltzing O; Diermeier-Daucher S; Buchdunger E; Wood J; Bold G; Breier G
    Int J Oncol; 2014 Dec; 45(6):2267-77. PubMed ID: 25340839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
    Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K
    Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
    Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ
    Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
    Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical application of fruquintinib on colorectal cancer.
    Chen Z; Jiang L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):713-721. PubMed ID: 31177854
    [No Abstract]   [Full Text] [Related]  

  • 14. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
    Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
    Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
    Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
    Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
    McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
    Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.